Table 2.
Patient- and tumor characteristics of the primary DCIS in relation to risk of a breast cancer event. Risk of an ipsilateral breast cancer event (IBE) including risk of in situ IBEs and invasive ipsilateral recurrence, respectively, and any invasive recurrence (IBCR) (univariate Cox regression analyses)
| Characteristics | Ipsilateral Breast Events (IBE) | in situ IBEs | invasive IBEs | Invasive Breast Cancer Recurrence (IBCR) |
|---|---|---|---|---|
| Among BCS (n = 359) | BCS | BCS | Among all (n = 458) | |
| HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | |
| Age (years) | ||||
| < 50 | Reference | Reference | Reference | Reference |
| 50–65 | 0.77 (0.44–1.31) | 0.92 (0.41–2.05) | 0.63 (0.30–1.32) | 0.68 (0.41–1.12) |
| > 65 | 1.19 (0.67–2.12) | 1.31 (0.55–3.11) | 1.09 (0.50–2.37) | 0.98 (0.57–1.66) |
| Detection mode | ||||
| Screening | Reference | Reference | Reference | Reference |
| Clinically | 1.78 (1.04–3.07) | 1.78 (0.81–3.91) | 2.09 (0.98–4.42) | 1.47 (0.93–2.35) |
| Type of Surgery | ||||
| BCS | - | - | - | Reference |
| Mastectomy | - | - | - | 0.55 (0.29–1.03) |
| RT after BCS | ||||
| No | Reference | Reference | Reference | Reference |
| Yes | 0.53 (0.33–0.86) | 0.50 (0.25–1.01) | 0.51 (0.27–0.98) | 0.91 (0.59–1.41) |
| Tumor size (mm) | ||||
| ≤ 25 | Reference | Reference | Reference | Reference |
| > 25 / multifocal | 1.14 (0.71–1.83) | 1.88 (0.97–3.62) | 0.64 (0.30–1.34) | 0.89 (0.55–1.45) |
| Nuclear grade | ||||
| Grade 1 | Reference | Reference | Reference | Reference |
| Grade 2 | 0.90 (0.41–1.96) | 1.05 (0.30–3.63) | 0.73 (0.27–1.99) | 0.82 (0.38–1.77) |
| Grade 3 | 0.83 (0.39–1.79) | 1.03 (0.30–3.49) | 0.63 (0.23–1.69) | 0.64 (0.30–1.37) |
| ER status | ||||
| Negative | Reference | Reference | Reference | Reference |
| Positive | 0.90 (0.52–1.55) | 0.80 (0.38–1.71) | 1.02 (0.47–2.22) | 1.16 (0.70–1.93) |
| PR status | ||||
| Negative | Reference | Reference | Reference | Reference |
| Positive | 0.83 (0.52–1.32) | 1.04 (0.53–2.02) | 0.66 (0.35–1.27) | 1.06 (0.69–1.63) |
RT radiotherapy, BCS breast conserving surgery, IBE ipsilateral breast events, IBCR invasive breast cancer recurrence